Neuroprotective strategies to prevent and treat Parkinson’s disease based on its pathophysiological mechanism

Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease after Alzheimer’s disease. PD exhibits clinical symptoms that include tremors, rigidity, and bradykinesia. Many drugs are available to treat PD, such as, l -dopa, COMT inhibitor, MAO-B inhibitor, and dopamine ag...

Full description

Saved in:
Bibliographic Details
Published inArchives of pharmacal research Vol. 40; no. 10; pp. 1117 - 1128
Main Authors Lee, Yujeong, Kim, Min-Sun, Lee, Jaewon
Format Journal Article
LanguageEnglish
Published Seoul Pharmaceutical Society of Korea 01.10.2017
대한약학회
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease after Alzheimer’s disease. PD exhibits clinical symptoms that include tremors, rigidity, and bradykinesia. Many drugs are available to treat PD, such as, l -dopa, COMT inhibitor, MAO-B inhibitor, and dopamine agonists, but these drugs simply compensate for dopamine loss in PD, and therefore, cannot completely suppress its symptoms or progression. Although the causes of PD are not clearly understood, common pathophysiological pathways, such as, oxidative stress, mitochondrial dysfunction, and neuroinflammation are considered to be etiological factors, and thus, many treatments and interventions have been developed to target these pathophysiological factors. This review describes the neuroprotective strategies devised based on current understanding of the pathophysiological mechanisms of PD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0253-6269
1976-3786
1976-3786
DOI:10.1007/s12272-017-0960-8